| Not Yet Recruiting | Imaging Acetadote Metabolism in Glioblastoma NCT07387666 | University of Texas Southwestern Medical Center | EARLY_Phase 1 |
| Not Yet Recruiting | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 / Phase 2 |
| Recruiting | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EG NCT07326566 | Black Diamond Therapeutics, Inc. | Phase 2 |
| Suspended | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma NCT06806228 | Petrov, Andrey | Phase 1 |
| Not Yet Recruiting | Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas NCT07384884 | King's College Hospital NHS Trust | N/A |
| Recruiting | Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System fo NCT07225621 | Alpheus Medical, Inc. | Phase 2 |
| Not Yet Recruiting | Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma NCT07274787 | University of Cincinnati | N/A |
| Recruiting | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoin NCT07179328 | Sunnybrook Health Sciences Centre | Phase 1 |
| Suspended | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) NCT06855628 | Stanford University | Phase 2 |
| Recruiting | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Gl NCT06388733 | Ivy Brain Tumor Center | Phase 3 |
| Withdrawn | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma NCT05973903 | Tel Aviv Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma NCT06396481 | Beijing Tiantan Hospital | EARLY_Phase 1 |
| Recruiting | Sonodynamic Therapy in Patients With Recurrent GBM NCT06039709 | Shayan Moosa, MD | Phase 1 |
| Active Not Recruiting | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent NCT05902169 | CarThera | Phase 3 |
| Recruiting | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367 | Orbus Therapeutics, Inc. | Phase 1 |
| Recruiting | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma NCT05954858 | Northwell Health | N/A |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection NCT06018363 | Dushu Lake Hospital Affiliated to Soochow University | Phase 1 / Phase 2 |
| Recruiting | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) NCT05979064 | Northwell Health | N/A |
| Recruiting | WBSI Guided Personalized Delivery of TTFields NCT05086497 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. NCT05686798 | Henry Ford Health System | Phase 1 |
| Recruiting | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation NCT05271240 | Northwell Health | Phase 3 |
| Unknown | A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM. NCT06092255 | Jiangsu Cancer Institute & Hospital | N/A |
| Terminated | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab NCT04681677 | Xoft, Inc. | Phase 2 |
| Active Not Recruiting | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma NCT05076513 | Nader Sanai | EARLY_Phase 1 |
| Terminated | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT NCT04763031 | Parkridge Medical Center | N/A |
| Active Not Recruiting | Surgical Nivolumab And Ipilimumab For Recurrent GBM NCT04606316 | Patrick Wen, MD | Phase 1 |
| Active Not Recruiting | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Gliobl NCT04528680 | Northwestern University | Phase 1 / Phase 2 |
| Completed | Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM NCT06538428 | Ain Shams University | — |
| Terminated | Infigratinib in Recurrent High-Grade Glioma Patients NCT04424966 | Nader Sanai | EARLY_Phase 1 |
| Completed | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients NCT04391595 | Nader Sanai | EARLY_Phase 1 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Suspended | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recu NCT04222309 | Northwell Health | Phase 1 |
| Active Not Recruiting | Niraparib/TTFields in GBM NCT04221503 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 NCT04074785 | University of Texas Southwestern Medical Center | EARLY_Phase 1 |
| Recruiting | Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Pa NCT04115761 | Ever Supreme Bio Technology Co., Ltd. | Phase 2 |
| Completed | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415 | MediciNova | Phase 1 / Phase 2 |
| Unknown | Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients NCT03758014 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | Phase 2 / Phase 3 |
| Unknown | To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Re NCT03746288 | CANbridge Life Sciences Ltd. | Phase 2 |
| Unknown | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme NCT03025893 | Amsterdam UMC, location VUmc | Phase 2 / Phase 3 |
| Active Not Recruiting | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM NCT03630289 | Northwell Health | N/A |
| Completed | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma NCT03341806 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Completed | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma NCT03451799 | Jethro Hu | Phase 1 |
| Completed | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma NCT03426891 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Gliobla NCT03367715 | NYU Langone Health | Phase 2 |
| Completed | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Express NCT03050736 | Kintara Therapeutics, Inc. | Phase 2 |
| Terminated | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma NCT03119064 | Brown University | Phase 1 / Phase 2 |
| Terminated | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM NCT03149575 | DelMar Pharmaceuticals, Inc. | Phase 3 |
| Completed | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurre NCT02717962 | Kintara Therapeutics, Inc. | Phase 2 |
| Terminated | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma NCT02663271 | University of Florida | Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteris NCT06914700 | Guangdong Provincial People's Hospital | — |
| Completed | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme NCT02465268 | University of Florida | Phase 2 |
| Recruiting | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastom NCT02861898 | Northwell Health | Phase 1 / Phase 2 |
| Recruiting | Integrative Analysis of Human Glioblastoma Multiforme NCT03005132 | Shanghai 10th People's Hospital | — |
| Unknown | The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients NCT02623231 | Tel-Aviv Sourasky Medical Center | Phase 2 / Phase 3 |
| Completed | A Phase 0 Study of AZD1775 in Recurrent GBM Patients NCT02207010 | St. Joseph's Hospital and Medical Center, Phoenix | EARLY_Phase 1 |
| Completed | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) NCT01856933 | Heinrich Elinzano, MD | Phase 2 |
| Completed | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme NCT01752491 | Joseph J. Cullen, MD, FACS | Phase 1 |
| Completed | FET-PET for Evaluation of Response of Recurrent GBM to Avastin NCT01756352 | Marcelo F. Di Carli, MD, FACC | Phase 2 |
| Completed | PVSRIPO for Recurrent Glioblastoma (GBM) NCT01491893 | Istari Oncology, Inc. | Phase 1 |
| Completed | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Gliob NCT01465347 | Diffusion Pharmaceuticals Inc | Phase 1 / Phase 2 |
| Completed | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma NCT01478178 | Kintara Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme NCT01205334 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Completed | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma NCT01112527 | Massachusetts General Hospital | Phase 2 |
| Unknown | Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma NCT01124539 | Arno Therapeutics | Phase 2 |
| Completed | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GB NCT01238237 | Northwell Health | Phase 1 |
| Unknown | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma NCT00683761 | TransMolecular | Phase 1 / Phase 2 |
| Unknown | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma NCT00591058 | TransMolecular | Phase 1 |
| Unknown | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer NCT00045968 | Northwest Biotherapeutics | Phase 3 |
| Completed | GW572016 to Treat Recurrent Malignant Brain Tumors NCT00107003 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma NCT00114309 | TransMolecular | Phase 2 |
| Available | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 0 NCT02146066 | Northwest Biotherapeutics | — |
| No Longer Available | Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment NCT06439849 | Petrov, Andrey | — |